Iovance Biotherapeutics downgraded by Truist
$IOVA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Truist downgraded Iovance Biotherapeutics from Buy to Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/16/2025 | $2.00 | Buy → Neutral | UBS |
| 5/12/2025 | Buy → Hold | Truist | |
| 5/9/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 10/24/2024 | $17.00 | Buy | UBS |
| 7/29/2024 | $19.00 → $10.00 | Overweight → Neutral | Piper Sandler |
| 11/20/2023 | $12.00 | Buy | Goldman |
| 9/18/2023 | $40.00 → $18.00 | Overweight | Barclays |
| 5/30/2023 | $11.00 → $17.00 | Equal Weight → Overweight | Wells Fargo |
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B